Literature DB >> 1717133

Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma.

M Y Altaee1, P J Johnson, J M Farrant, R Williams.   

Abstract

A 20-year experience with 112 patients with cholangiocarcinoma was reviewed with reference to the demographic, etiologic, and clinical features and prognosis in the following two types: peripheral (originating from the intrahepatic small duct radicles) and hilar (originating from the major hepatic ducts at or near the junction of the right and left hepatic ducts). Seventy of the 112 patients were in the hilar group, and 42 were in the peripheral group. Prolonged high alcohol consumption was a prominent feature in both categories (45% and 37%, respectively). Among the women, 35% of those with the peripheral tumor had used oral contraceptive preparations. The major identifiable etiologic factor among the hilar tumors was ulcerative colitis, with or without sclerosing cholangitis, which was documented in 20 of 70 cases (28.6%), with an additional 4 patients having Crohn's disease. The hilar group mainly had obstructive jaundice initially, whereas abdominal pain and weight loss were the predominant symptoms in the peripheral type. Tumor recurrence was frequent in those undergoing resection or transplantation, and none of those undergoing chemotherapy or radiation therapy showed any objective evidence of response. Overall median survival time was poor in both groups at 12 months.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717133     DOI: 10.1002/1097-0142(19911101)68:9<2051::aid-cncr2820680934>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.

Authors:  William C Palmer; Tushar Patel
Journal:  J Hepatol       Date:  2012-03-13       Impact factor: 25.083

2.  Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows.

Authors:  Susan Tsai; Hari Nathan; Timothy M Pawlik
Journal:  Updates Surg       Date:  2010-08

3.  Antitumor effect of the paclitaxel-eluting membrane in a mouse model.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee; Jin Hee Maeng; In Suh Park; Sangsoo Park
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

4.  Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives.

Authors:  Eleni Vrettou; Prodromos Hytiroglou; Nikolaos Sikas; Ioannis Soultoyannis; Zachary D Goodman
Journal:  Virchows Arch       Date:  2005-04-07       Impact factor: 4.064

5.  Current imaging strategies of primary and secondary neoplasms of the liver.

Authors:  Linda Fielding
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

6.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

7.  Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.

Authors:  Ashwani K Singal; Jean-Nicolas Vauthey; James J Grady; John R Stroehlein
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-05       Impact factor: 4.553

Review 8.  Hepatic angiomyolipoma developing during the follow-up of ulcerative colitis: report of a case and review of the literature.

Authors:  S Suzuki; S Nakamura; H Ishida; T Sakaguchi; A Serizawa; H Konno; S Baba; H Muro; I Kosugi; E Gu
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

9.  Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type.

Authors:  Sang Hyub Lee; Joo Kyung Park; Won Jae Yoon; Jun Kyu Lee; Ji Kon Ryu; Yong Bum Yoon; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

Review 10.  Multi-disciplinary treatment for cholangiocellular carcinoma.

Authors:  Mitsugi Shimoda; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.